Toxicity Management and Symptom Control in Advanced RCC: Playbook Update

Join Nazy Zomorodian, NP, RNC, MSN, CUNP, CCRC, as she provides an essential update on managing toxicities in patients with advanced renal cell carcinoma (RCC). With exciting advances in immunotherapy and targeted therapies transforming RCC treatment, nurses play a critical role in managing potential side effects. This activity will arm you with practical, up-to-date strategies to ensure your patients receive the best care while minimizing treatment-related toxicities.

STATEMENT OF NEED

Each year, more than 430,000 cases of kidney cancer are diagnosed worldwide. Renal cell carcinoma (RCC), which includes clear cell, papillary, and chromophobe subtypes, is the most common form of kidney cancer. In recent years, the rise of immunotherapy and targeted therapy has contributed to a revolution in the treatment of RCC, with several novel agents and combinations granted approval. While these treatments demonstrate superior efficacy compared with previous standards, patients may experience adverse events that carry the risk of dose reductions or drug discontinuations, and safety and tolerability remain crucial considerations in the care of patients receiving novel therapies for RCC (Tucci et al, 2024). Therefore, it is vital that nurses remain up to date on prevention and management strategies for toxicities associated with novel immunotherapies and targeted therapies in order to deliver optimal care to their patients. In this activity, Nazy Zomorodian, NP, RNC, MSN, CUNP, CCRC, Director of the GU Clinical Trials Program at David Geffen School of Medicine at UCLA and the Institute of Urologic Oncology at UCLA, provides a playbook update on toxicity management and symptom control in advanced RCC. 

TARGET AUDIENCE

Oncology and urology nurses, nurse practitioners, clinical nurse specialists, and other healthcare professionals involved in the treatment of patients with renal cell carcinoma (RCC).

LEARNING OBJECTIVES

Upon completion of this activity, participants should be able to:

• Differentiate the mechanisms of action (MOAs) of novel therapeutic strategies for advanced RCC
• Appraise the efficacy and safety profiles of novel immunotherapies and targeted therapies for advanced RCC
• Assess strategies to optimize treatment safety and tolerability and ensure the provision of patient-centered RCC care

REGISTRATION

There is no fee to participate in or claim NCPD credit for this activity.

Provided by

JOINTLY ACCREDITED PROVIDER

In support of improving patient care, i3 Health is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

NURSING CONTINUING PROFESSIONAL DEVELOPMENT 

A maximum of 1.0 ANCC contact hour may be earned by learners who successfully complete this nursing continuing professional development activity. This activity has been designated for 1.0 ANCC contact hour of pharmacology credit for Advanced Practice Registered Nurses.

Provider approved by the California Board of Registered Nursing, Provider Number 15824, for 1.0 ANCC contact hour.

The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points.

ONCC review is only for designating content to be used for recertification points and is not for NCPD accreditation. NCPD programs must be formally approved for contact hours by an acceptable accreditor/approver of NCPD to be used for recertification by ONCC. If the NCPD provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification may be used in relation to the program.

OCN®, CPHON®, CBCN®, AOCNP®, AOCNS®, and BMTCN® renewal candidates may apply 1.0 ILNA point toward:

• Care Continuum (OCN®, CBCN®, CPHON®, AOCNP®)
• Oncologic Emergencies (OCN®, CPHON®, AOCNP®)
• Oncology Nursing Practice (OCN®)
• Roles of the APRN (AOCNP®)
• Symptom Management, Palliative Care, Supportive Care (OCN®, CPHON®, AOCNP®)
• Treatment (OCN®, CBCN®, AOCNP®, CPHON®)

Please note that some of the course content applies to multiple content areas. The numerical value above indicates the maximum amount of points that can be claimed in each domain. The total amount of ILNA points claimed may not exceed the total amount of NCPD awarded from this course.

DISCLOSURE OF RELEVANT FINANCIAL INFORMATION WITH INELIGIBLE COMPANIES

i3 Health endorses the standards of the ANCC that require everyone in a position to control the content of a NCPD activity to disclose all financial relationships with ineligible companies that are related to the content of the NCPD activity. NCPD activities must be balanced, independent of commercial bias, and promote improvements or quality in health care. All recommendations involving clinical medicine must be based on evidence accepted within the medical profession.

A conflict of interest is created when an individual has an opportunity to affect NCPD content about products or services of a ineligible company with which he/she has a financial relationship, which therefore may bias their opinions and teaching. This may include receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, stocks, or other financial benefits.

i3 Health will identify, review, and mitigate all relevant financial relationships that speakers, authors, or planners disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. i3 Health does not endorse any products or services.

Relevant financial relationships exist between the following individuals and ineligible companies:

The i3 Health planners, reviewers, and managers have nothing to disclose.

Nazy Zomorodian, NP, RNC, MSN, CUNP, CCRC, has no relevant financial relationships to disclose. 

i3 Health has mitigated all relevant financial relationships.

COMMERCIAL SUPPORT

This activity is supported by an independent educational grant from Merck Sharp & Dohme LLC.

Aggregate participant data will be shared with commercial supporters of this activity.